EX-10.3 4 dex103.htm MASTER CLINICAL SERVICES AGREEMENT MASTER CLINICAL SERVICES AGREEMENT FORENAP PHARMA – TARGACEPT MASTER CLINICAL SERVICES AGREEMENT between TARGACEPT, INC. and FORENAP PHARMA EURL Page 1 / 33 MASTER CLINICAL SERVICES AGREEMENT...Master Clinical Services Agreement • May 5th, 2020
FORENAP PHARMA EURL, having its registered offices at 27 rue du 4ème RSM – B.P. 27, F-68250 ROUFFACH, France, represented by Rémy LUTHRINGER, Ph.D., CEO, hereinafter referred to as “FORENAP”
MASTER SERVICES AGREEMENTMaster Clinical Services Agreement • October 17th, 2008 • Peplin Inc • Pharmaceutical preparations • New Jersey
THIS CLINICAL MASTER SERVICES AGREEMENT (the “Agreement”) is entered into as of the effective date, March 6, 2008 (“Effective Date”), by and between TKL Research, Inc., whose offices are located at 365 W. Passaic Street, Rochelle Park, NJ 07662 (together with its, agents and/or affiliates, “TKL”), and Peplin Operations Pty Ltd. located at Level 2, 1 Breakfast Creek Rd, Newstead, Queensland 4006, Australia (“Sponsor”).
ANDMaster Clinical Services Agreement • October 22nd, 2009 • Amarin Corp Plc\uk • Pharmaceutical preparations • England
MASTER CLINICAL SERVICES AGREEMENTMaster Clinical Services Agreement • May 23rd, 2007 • NovaCardia Inc • Pharmaceutical preparations
As a condition of participating as a clinical investigator in the protocol entitled, " " (the "Study") sponsored by NovaCardia, Inc. ("NovaCardia"), please provide the appropriate information and responses to the following statements.
FOIA CONFIDENTIAL TREATMENT REQUEST BY HEDGEPATH PHARMACEUTICALS, INC. IRS EMPLOYER IDENTIFICATION NUMBER 30-0793665Master Clinical Services Agreement • August 14th, 2015 • HedgePath Pharmaceuticals, Inc. • Services-commercial physical & biological research • California
This Master Clinical Services Agreement (this “Agreement”) is executed as of 15 June, 2015 and made effective as of 29 September, 2014 (“Effective Date”), by and between SciQuus, Inc., a Delaware corporation, having a place of business at 4250 Executive Square, Suite 450, La Jolla, CA 92037 (hereinafter “SciQuus”), and HedgePath Pharmaceuticals, Inc., a Delaware corporation having a place of business at 324 S. Hyde Park Avenue, Ste. 350 Tampa, Florida 33606 (hereinafter “Sponsor”). Sponsor and SciQuus are sometimes referred to herein individually as a “Party” and together as the “Parties.”
MASTER CLINICAL SERVICES AGREEMENT THIS AGREEMENT, effective as of January 1, 1997 by and between BRACCO S.p.A., a company incorporated in Italy, having its legal seat and principal place of business at Via Egidio Folli, 50 - 20134 Milano, Italy...Master Clinical Services Agreement • July 24th, 1997 • Bio Imaging Technologies Inc • Services-medical laboratories
MASTER CLINICAL SERVICES AGREEMENTMaster Clinical Services Agreement • May 27th, 2021 • Acurx Pharmaceuticals, LLC • Pharmaceutical preparations • Delaware
This MASTER CLINICAL SERVICES AGREEMENT (“Agreement”), effectively dated as of the last date of authorized signature herein (“Effective Date”), is made by and between Acrux Pharmaceuticals, LLC, a Delaware limited liability company (“Sponsor”), with principal offices located at 22 Camelot Court, White Plains, NY 10603 and Syneos Health, LLC, a Delaware limited liability company, with principal offices located in the United States at 1030 Sync Street, Morrisville, North Carolina 27560, together with Syneos Health UK Limited, a company with principal offices located at Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, GU14 7BF, England, Europe (“Syneos Health”).
MASTER CLINICAL SERVICES AGREEMENT by and between NEUROBIOLOGICAL TECHNOLOGIES, INC. and ICON CLINICAL RESEARCH LIMITEDMaster Clinical Services Agreement • September 13th, 2007 • Neurobiological Technologies Inc /Ca/ • Biological products, (no disgnostic substances) • Delaware
This Master Clinical Services Agreement (this “Agreement”) is made as of January 16, 2007 by and between Neurobiological Technologies, Inc., a Delaware corporation with an address of 2000 Powell Street, Suite 800, Emeryville, CA 94608 (“Sponsor”), and ICON Clinical Research Limited, a company formed under the laws of Ireland with offices at South County Business park, Leopardstown, Dublin, Ireland (“Service Provider”).
MASTER CLINICAL SERVICES AGREEMENT between URIGEN HOLDINGS, INC. and CLINIMETRICS RESEARCH CANADA, INC.Master Clinical Services Agreement • March 30th, 2007 • Valentis Inc • Biological products, (no disgnostic substances) • Ontario
This Master Services Agreement (this “Agreement”) is made as of October 4, 2005 by and between Urigen, Inc., a Canadian corporation with offices located at Urigen Holdings, Inc., 515 West Hastings Street, Suite 7100, Vancouver, BC V6B 5K3, Canada (“Urigen”) and Clinimetrics Research Canada, Inc., an Ontario corporation with offices at 2655 North Sheridan Way, Suite 120, Mississauga, Ontario L5K2P8, Canada (“Service Provider”).
